Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded a decrease of -12.26%. However, over the last six months, the performance has been stronger by -77.26%. The price of KROS increased 23.80% over the last 30 days. And in the last five days, it has surged by 9.03%.
Keros Therapeutics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $72.37 on 12/09/24, while the lowest price for the same period was registered at $9.12 on 04/09/25.
52-week price history of KROS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Keros Therapeutics Inc’s current trading price is -80.81% away from its 52-week high, while its distance from the 52-week low is 52.30%. The stock’s price range during this period has varied between$9.12 and $72.37. The Keros Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.87 million for the day, a figure considerably lower than their average daily volume of 1.16 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Keros Therapeutics Inc (KROS) has experienced a quarterly rise of 21.74% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 563.41M and boasts a workforce of 169 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 18.51, with a change in price of -42.03. Similarly, Keros Therapeutics Inc recorded 1,445,923 in trading volume during the last 100 days, posting a change of -75.16%.
KROS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for KROS stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.03.
KROS Stock Stochastic Average
As of today, Keros Therapeutics Inc’s raw stochastic average for the last 50 days stands at 85.95%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 85.95%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 92.24% and 95.41%, respectively.
